This innovation marks a significant shift in the contraceptive landscape, allowing men to share the responsibility of birth control in a safe and reversible way.

A groundbreaking male contraceptive method, designed to offer a long-term alternative to condoms and vasectomy, has shown promising results in early clinical trials.

The American biotechnology company Contraline has developed a device called Adam, which provides effective contraception for up to two years with a single injection. According to The Guardian on April 24, the product has successfully completed Phase I clinical trials.

Unlike traditional methods, Adam works by injecting a water-based hydrogel into the vas deferens — the duct that carries sperm from the testes. The hydrogel acts as a physical barrier, blocking sperm from being released during ejaculation.

“The hydrogel is soft and jelly-like in texture, made mostly of water,” researchers explained. The sperm, once blocked, is naturally reabsorbed by the body, leaving men to ejaculate semen that no longer contains sperm.